These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1421123)

  • 1. The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome.
    Dzoljic MR; Bokszanska A; Korenhof AM; Kaplan CD; Dzoljic M; Rupreht J; Zijlstra FJ; Brinkman EC; Cappendijk SL
    Neuroreport; 1992 Jul; 3(7):637-40. PubMed ID: 1421123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enkephalinase inhibitors attenuate naloxone-precipitated withdrawal syndrome.
    Dzoljic MR
    NIDA Res Monogr; 1986; 75():575-8. PubMed ID: 3123978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome.
    Maldonado R; Daugé V; Callebert J; Villette JM; Fournié-Zaluski MC; Feger J; Roques BP
    Eur J Pharmacol; 1989 Jun; 165(2-3):199-207. PubMed ID: 2776828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phelorphan, an inhibitor of enzymes involved in the biodegradation of enkephalins, affected the withdrawal symptoms in chronic morphine-dependent rats.
    Haffmans J; Walsum MV; van Amsterdam JC; Dzoljic MR
    Neuroscience; 1987 Jul; 22(1):233-6. PubMed ID: 2888045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan.
    Livingston SJ; Sewell RD; Rooney KF; Smith HJ
    Psychopharmacology (Berl); 1988; 94(4):540-4. PubMed ID: 3131801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
    Maldonado R; Fournié-Zaluski MC; Roques BP
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Apr; 345(4):466-72. PubMed ID: 1620246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms.
    Haffmans J; Dzoljic MR
    Gen Pharmacol; 1987; 18(1):103-5. PubMed ID: 3549428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor.
    Knisely JS; Beardsley PM; Aceto MD; Balster RL; Harris LS
    Drug Alcohol Depend; 1989 Apr; 23(2):143-51. PubMed ID: 2702924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic inhibition of enkephalinase induces changes in the antinociceptive and locomotor effects of the enkephalinase inhibitor acetorphan in rats.
    Bousselmame R; Eustache M; Michael-Titus A; Costentin J
    Neuropharmacology; 1991 Aug; 30(8):865-70. PubMed ID: 1780043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral excitatory effects of two enkephalinase inhibitors, acetorphan and thiorphan, and an enkephalin analogue, [D-Ala2-Met5]-enkephalinamide, on uterine motility in periparturient rats in vivo and in vitro.
    Adjroud O
    J Reprod Fertil; 1995 Jul; 104(2):181-6. PubMed ID: 7473405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor.
    Lecomte JM; Costentin J; Vlaiculescu A; Chaillet P; Marcais-Collado H; Llorens-Cortes C; Leboyer M; Schwartz JC
    J Pharmacol Exp Ther; 1986 Jun; 237(3):937-44. PubMed ID: 3519939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
    Sinchaisuk S; Ho IK; Rockhold RW
    Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the enkephalinase inhibitor SCH 34826 on the sleep-waking cycle and EEG activity in the rat.
    Trampus M; Conti A; Marzanatti M; Monopoli A; Ongini E
    Neuropharmacology; 1990 Mar; 29(3):199-205. PubMed ID: 2325830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented analgesic effects of enkephalinase inhibitors combined with transcranial electrostimulation.
    Malin DH; Lake JR; Hamilton RF; Skolnick MH
    Life Sci; 1989; 44(19):1371-6. PubMed ID: 2716474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of delta opioid receptors in the effects of inhibitors of enkephalin-degrading peptidases on the horizontal and vertical components of locomotion in mice.
    Michael-Titus A; Dourmap N; Costentin J; Schwartz JC
    Neuropeptides; 1990 Feb; 15(2):89-100. PubMed ID: 1981928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization of mu-opioid receptors does not modify the analgesia induced by an enkephalinase inhibitor.
    Bousselmame R; Michael-Titus A; Costentin J
    Eur J Pharmacol; 1991 Oct; 203(2):295-7. PubMed ID: 1666049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive effects by cysteine protease inhibitors on naloxone-precipitated withdrawal jumping in morphine-dependent mice.
    Tan-No K; Sato T; Shimoda M; Nakagawasai O; Niijima F; Kawamura S; Furuta S; Sato T; Satoh S; Silberring J; Terenius L; Tadano T
    Neuropeptides; 2010 Jun; 44(3):279-83. PubMed ID: 20189644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinociceptive effects of the enkephalinase inhibitor, SCH 34826, in the snail, Cepaea nemoralis.
    Saksida LM; Galea LA; Kavaliers M
    Peptides; 1993; 14(4):763-5. PubMed ID: 8234022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological properties of 2-[S-acetylthiorphan]-1,3- diacylaminopropan-2-ol derivatives as chimeric lipid drug carriers containing an enkephalinase inhibitor.
    Lambert DM; Mergen F; Berens CF; Poupaert JH; Dumont P
    Pharm Res; 1995 Feb; 12(2):187-91. PubMed ID: 7784331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic.
    Chipkin RE; Berger JG; Billard W; Iorio LC; Chapman R; Barnett A
    J Pharmacol Exp Ther; 1988 Jun; 245(3):829-38. PubMed ID: 3164388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.